May 17, 2004
In Print Photo of Haber by Steve Gilbert/Johnson courtesy of Bruce Johnson From Focus: Mutated Target Gives Potency to Lung Cancer Medication The question of why the targeted cancer drug gefitinib (Iressa) is spectacularly effective on 10 percent of lung cancers while leaving many untouched has been answered by two independent HMS studies. They found that mutations in gefitinib's target receptor determine whether tumors respond to the drug or not. Senior authors, including Daniel Haber (left) and Bruce Johnson, say the work supports the general view that targeting mutations crucial for tumor growth may be an effective approach against cancer.   Publications Online BBS Bulletin Focus HMI World HSTconnector MD-PhD Newsletter MedEd News Mentations On The Brain   Related Links InteliHealth Harvard Health Publications		Headlines Quality of Life Continues to Change Long-term After Treatment for Prostate Cancer Upcoming Research Seminar: Aquaporin Water Channels: Blueprint for a Molecular Plumbing System Peter Agre, Nobel Laureate in Chemistry May 26, 2004 4:00 p.m. Lab Works A multimedia site featuring Harvard Medical research		Spotlight Photo by Jeff Cleary Peabody Prevails in Longwood Olympics The May 7 Student Olympics saw the Peabody Society best all comers in a comely competition on the HMS Quad. See the link for more photos. Student Scene Photo by Jeff Cleary Breastfeeding Rights and Wrongs Tarayn Grizzard believes that physicians would do a better job of encouraging mothers to breastfeed their infants if women doctors who have just given birth were themselves more successful at breastfeeding their babies.

Calendar | Jobs | Harvard Medical School Home | Hospitals | Back Issues | Feedback | Home Copyright 2004 by the President and Fellows of Harvard College